<DOC>
	<DOCNO>NCT00854126</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I study evaluate safety , tolerability , pharmacokinetics escalate oral dos GDC-0980 administer patient incurable , locally advanced metastatic solid malignancy NHL progress failed respond least one prior regimen standard therapy .</brief_summary>
	<brief_title>A Study Evaluating GDC-0980 Administered Once Weekly Patients With Refractory Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically document , incurable , locally advanced metastatic solid malignancy , NHL without leukemic phase , progress despite standard care therapy standard therapy proven clinical benefit A biopsyaccessible lesion tissue obtain safely Evaluable measurable disease per RECIST and/or follow : prostate cancer patient nonmeasurable disease eligible two rise prostatespecific antigen ( PSA ) level meet PSA Working Group criteria progression prior initiation study treatment ; ovarian cancer patient nonmeasurable disease eligible two rise CA125 level great ULN &gt; = 2 week apart prior initiation study treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 screen Life expectancy &gt; = 12 week Adequate hematologic organ function within 28 day initiation GDC0980 Documented willingness use effective mean contraception men woman participate study For patient participate DCEMRI assessment : least one metastatic lesion measure &gt; /= 3 cm liver &gt; /= 2 cm elsewhere ( lung mediastinum lesion ineligible ) least one dimension ( CT scan ) Leptomeningeal disease manifestation current malignancy History Type 1 2 diabetes mellitus require regular medication Grade &gt; =2 hypercholesterolemia hypertriglyceridemia Malabsorption syndrome condition would interfere enteral absorption Known untreated malignancy brain spinal cord , treat brain metastasis radiographically stable &gt; = 3 month Congenital long QT syndrome screen QTc &gt; 470 msec Active congestive heart failure ventricular arrhythmia require medication Ejection fraction &lt; 50 % LLN ( whichever high ) , determine echocardiogram MUGA scan Active infection require IV antibiotic Requirement daily supplemental oxygen DLCO &lt; 50 % predict value correct hemoglobin alveolar volume Uncontrolled hypomagnesemia Hypercalcemia require continue use bisphosphonate therapy Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Uncontrolled ascites require frequent paracentesis Known HIV infection Any disease , active control pulmonary dysfunction , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Significant traumatic injury within 4 week Day 1 Major surgical procedure within 4 week prior initiation GDC0980 Treatment chemotherapy , hormonal therapy ( except hormone replacement therapy , oral contraceptive , GnRH agonists antagonist prostate cancer ) , immunotherapy , biologic therapy , radiation therapy ( except palliative radiation bony metastasis ) , herbal therapy cancer therapy within 3 week prior initiation GDC0980 Palliative radiation bony metastasis within 2 week prior initiation GDC0980 Need chronic corticosteroid therapy &gt; =10 mg prednisone per day equivalent dose antiinflammatory corticosteroid immunosuppressant Treatment investigational agent within 4 week prior initiation GDC0980 Unresolved toxicity prior therapy except alopecia Grade 1 peripheral neuropathy Pregnancy lactation For patient participate DCEMRI assessment , contraindication MRI examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Carcinogenic Tumors</keyword>
</DOC>